Related Experiment Videos
Immunomic analysis of human sarcoma.
Sang-Yull Lee1, Yuichi Obata, Masahiro Yoshida
1Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. .
Summary
Cancer/testis (CT) antigens are highly expressed in synovial sarcomas but rarely trigger immune responses. Researchers identified a novel CT antigen, NY-SAR-35, a potential target for cancer vaccines and immunotherapies.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Cancer/testis (CT) antigens are immunogenic and have restricted expression patterns, making them key targets in cancer immunology.
- Synovial sarcomas frequently express CT antigens like NY-ESO-1 and MAGE-A3, suggesting potential for immune recognition.
Purpose of the Study:
- To investigate humoral immune responses to CT antigens in sarcoma patients.
- To identify novel cancer-related antigens using serum antibody screening (SEREX) in synovial sarcoma.
Main Methods:
- Serum samples from 54 sarcoma patients were tested for antibodies against a panel of CT antigens.
- SEREX was performed on cDNA libraries from synovial sarcoma cell lines and normal testis using patient sera.
- Identified antigens were analyzed for cancer-specific serological profiles.
Main Results:
- Only two patients showed detectable antibodies to CT antigens, specifically against NY-ESO-1, indicating low immunogenicity in this cohort.
- SEREX identified 113 distinct antigens, with 39 previously known and 59% lacking cancer-specific serological profiles.
- A novel CT antigen, NY-SAR-35, was discovered, exhibiting testis and multiple cancer type expression (sarcoma, melanoma, lung, esophageal, breast).
Conclusions:
- Despite high expression in sarcoma, CT antigens do not frequently elicit humoral immune responses in patients.
- NY-SAR-35 is a novel, cancer-related antigen with a broad expression profile, representing a promising candidate for cancer vaccines and immunotherapies.